Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CHKA | P35790 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576618 | 0.98 | MAPT (0.53) | MAPTNPC1RAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL9881494 | 0.98 | MAPT (0.53) | MAPTNPC1RAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL8290040 | 0.86 | CHKA (0.51) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL231910 | 0.84 | CHRNB2 (0.68) | CHRNB2CHRNA4 | |
| SCHEMBL82236 | 0.84 | MAPT (0.50) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL23107765 | 0.83 | MAPT (0.46) | MAPTNPC1RAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL20248039 | 0.83 | L3MBTL3 (0.64) | ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL23107766 | 0.83 | MAPT (0.46) | MAPTNPC1RAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL17297906 | 0.82 | USP2 (0.49) | MAPTNPC1RAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL255401 | 0.82 | MAPT (0.55) | MAPTNPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0421762-A1 | Novel nicotine analogs and method | Philip Morris Products Inc. (US) | 1991-04-10 | — | — | EP | claimed |
| CN-117388406-A | Determination method for chiral resolution of 1-methyl-2 alpha- (6-methyl-3-pyridyl) pyrrolidine | 东莞市鸿馥生物科技有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| EP-3532473-B1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2021078132-A1 | INHIBITORS OF MTOR-MEDIATED INDUCTION OF AUTOPHAGY | SIRONAX LTD (GB) | 2021-04-29 | — | — | WO | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-20170174681-A1 | Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof | SANOFI (FR) | 2017-06-22 | — | — | US | disclosed |
| US-20170174681-A1 | Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof | SANOFI (FR) | 2017-06-22 | — | — | US | disclosed |
| EP-2804868-B1 | PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9403839-B2 | Pyran-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20150005304-A1 | Pyran-Spirocyclic Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2013109521-A1 | PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-25 | — | — | WO | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | MAPT 4172/4885NPC1 3990/4885RAB9A 1796/4885 |
| US-20170174681-A1 | Pyrazolopyridine Derivatives, Preparation Process Therefor And Therapeutic Use Thereof | FGF1, FGF2, FGFR1 | MAPT 4077/4885NPC1 2420/4885RAB9A 2635/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | MAPT 4172/4885NPC1 3990/4885RAB9A 1796/4885 |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ1, KCNC1 | MAPT 2611/4885NPC1 675/4885RAB9A 1016/4885 |
| US-20150005304-A1 | Pyran-Spirocyclic Piperidine Amides as Modulators of Ion Channels | TRPV1, KCNJ2, KCNJ1 | MAPT 2202/4885NPC1 657/4885RAB9A 1132/4885 |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | CDK4, CDKL4, CDK2 | MAPT 2440/4885NPC1 4258/4885RAB9A 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.